NDC 0409-7447 - Cimetidine in Sodium Chloride
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 0409-7447
- Package NDCs from labels
- 0409-7447-16
- Manufacturer
- HOSPIRA, INC.
- Effective date
- 2006-04-13
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| CIMETIDINE in 0.9% Sodium Chloride Injection, USP | HOSPIRA, INC. | 2006-04-13 | Human prescription drug label |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| Cimetidine | ACTIVE INGREDIENT | 80061L1WGD | CIMETIDINE IN SODIUM CHLORIDE (CIMETIDINE AND SODIUM CHLORIDE) INJECTION, SOLUTION [HOSPIRA, INC.] | 1 | |
| Cimetidine | ACTIVE MOIETY | 80061L1WGD | CIMETIDINE IN SODIUM CHLORIDE (CIMETIDINE AND SODIUM CHLORIDE) INJECTION, SOLUTION [HOSPIRA, INC.] | 1 | |
| Hydrochloric Acid | INACTIVE INGREDIENT | QTT17582CB | CIMETIDINE IN SODIUM CHLORIDE (CIMETIDINE AND SODIUM CHLORIDE) INJECTION, SOLUTION [HOSPIRA, INC.] | 1 | |
| Sodium Chloride | INACTIVE INGREDIENT | 451W47IQ8X | CIMETIDINE IN SODIUM CHLORIDE (CIMETIDINE AND SODIUM CHLORIDE) INJECTION, SOLUTION [HOSPIRA, INC.] | 1 | |
| Sodium Hydroxide | INACTIVE INGREDIENT | 55X04QC32I | CIMETIDINE IN SODIUM CHLORIDE (CIMETIDINE AND SODIUM CHLORIDE) INJECTION, SOLUTION [HOSPIRA, INC.] | 1 | |
| Water | INACTIVE INGREDIENT | 059QF0KO0R | CIMETIDINE IN SODIUM CHLORIDE (CIMETIDINE AND SODIUM CHLORIDE) INJECTION, SOLUTION [HOSPIRA, INC.] | 1 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Docetaxel | DOCETAXEL | Hospira, Inc. | 6b9999bb-869e-4d25-838c-23c3ab280044 | 2025-01-31 | Boxed warning, Warnings, Adverse reactions | Hospira, Inc. |
| Sodium Chloride | SODIUM CHLORIDE | Baxter Healthcare Corporation | 93aeac13-41de-4452-9f38-d6b4f38ada30 | 2025-01-24 | Sodium Chloride | |
| Docetaxel | DOCETAXEL ANHYDROUS | Hospira, Inc. | 644c5035-20d2-4686-beaa-bef08e99051c | 2025-01-20 | Boxed warning, Warnings, Adverse reactions | Hospira, Inc. |
| Docetaxel | DOCETAXEL ANHYDROUS | Hospira, Inc. | 00c61d11-d6b7-4618-b6f6-2592dbcc8af7 | 2025-01-20 | Boxed warning, Warnings, Adverse reactions | Hospira, Inc. |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | Hospira, Inc. | 91c050cf-3b2d-48bc-7297-e8dc68225e5a | 2025-01-16 | Warnings, Adverse reactions | Hospira, Inc. |
| SODIUM CHLORIDE | SODIUM CHLORIDE | HF Acquisition Co LLC, DBA HealthFirst | 998a2a47-5c79-2efd-e053-2995a90a8fac | 2025-01-08 | Adverse reactions | SODIUM CHLORIDE |
| SODIUM CHLORIDE | SODIUM CHLORIDE | HF Acquisition Co LLC, DBA HealthFirst | 7da788fc-3481-527f-e053-2a91aa0af6ac | 2025-01-08 | Adverse reactions | SODIUM CHLORIDE |
| DOBUTAMINE | DOBUTAMINE | Hospira, Inc. | dc537761-d5f4-488d-24ab-b2bcd2b17b7a | 2024-12-09 | Warnings, Adverse reactions | Hospira, Inc. |
| Sodium Chloride | SODIUM CHLORIDE | Baxter Healthcare Company | 464c2d78-5c88-4668-a039-56dd3c1c9b20 | 2024-12-03 | Sodium Chloride | |
| CIMETIDINE | CIMETIDINE | Aurobindo Pharma Limited | ebd53065-c080-4045-a398-64d3f3b1460f | 2024-11-14 | Adverse reactions | CIMETIDINE |
| Sodium Chloride | SODIUM CHLORIDE | Baxter Healthcare Company | 99a15716-bbb9-4e33-a48d-20c58b81f392 | 2024-11-13 | Sodium Chloride | |
| Cimetidine | CIMETIDINE | A-S Medication Solutions | cf1626a1-ccf6-4759-b2ab-22c7f3873d84 | 2024-11-08 | Adverse reactions | Cimetidine |
| Meropenem | MEROPENEM | Hospira, Inc. | e9b6555f-20a1-4415-bb80-3d034cfab95b | 2024-11-06 | Warnings, Adverse reactions | Hospira, Inc. |
| Meropenem | MEROPENEM | Hospira, Inc. | 092ebd9b-77a0-4877-afc3-dd8211730f71 | 2024-11-06 | Warnings, Adverse reactions | Hospira, Inc. |
| Ertapenem | ERTAPENEM | Hospira, Inc. | 178a0356-4f6c-47fb-9913-f325a3c72f7b | 2024-11-06 | Warnings, Adverse reactions | Hospira, Inc. |
| Sodium Chloride | SODIUM CHLORIDE | Hospira, Inc. | 8eb172da-dcd4-4660-4a8f-ad44a14b4af7 | 2024-11-06 | Adverse reactions | Sodium Chloride Hospira, Inc. |
| Cefepime | CEFEPIME | Hospira, Inc. | e80c27e2-164d-4836-ba24-c160d75dc5d3 | 2024-11-06 | Warnings, Adverse reactions | Hospira, Inc. |
| Sodium Chloride | SODIUM CHLORIDE | Fresenius Kabi USA, LLC | c44b0fdb-33df-4747-b443-5fb4deb456cb | 2024-10-11 | Warnings, Adverse reactions | Sodium Chloride |
| Docetaxel | DOCETAXEL | Hospira, Inc. | 3104aab1-cd6e-4ad2-8e0a-286a0c5d1940 | 2024-09-19 | Boxed warning, Warnings, Adverse reactions | Hospira, Inc. |
| Docetaxel | DOCETAXEL ANHYDROUS | Hospira, Inc. | a0ec4bcc-93ea-4c41-a4b6-95ec19491807 | 2024-08-22 | Boxed warning, Warnings, Adverse reactions | Hospira, Inc. |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.